Clinical Trial Update: A Study of RTA 901 (BIIB143) in Participants With Diabetic Peripheral Neuropathic Pain [Phase 2]

View source ↗

Summary

A Phase 2 study of RTA 901 (BIIB143) in participants with diabetic peripheral neuropathic pain was terminated, and trial results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Peripheral Neuropathy

Drugs mentioned

• RTA 901 (BIIB143) (RTA 901)

Snippet

Sponsor: Reata, a wholly owned subsidiary of Biogen | Conditions: Diabetic Peripheral Neuropathic Pain | Phase 2 | Status: TERMINATED | Results posted: 2025-12-15